{"classes":[{"categories":[{"measurements":[{"comment":"A complete confidence interval (CI) cannot be calculated because there are too few patients in the data set.","groupId":"OG000","lowerLimit":"42","upperLimit":"NA","value":"99"},{"comment":"CI cannot be calculated because there is only 1 patient in the data set.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Duration of Response was defined as the time from date of first response (Complete Response \\[CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).\\] or Partial Response \\[PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.\\]) to the date when Progressive Disease (PD: at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study or unequivocal progression of existing non-target lesions, or appearance of new lesions.) is first documented, or to the date of death, whichever occurs first, according to RECIST v1.1. Subjects still having CR or PR and have not died at the time of analysis were censored at their last date of tumor evaluation. Duration of response defined for responders only, i.e CR or PR. Results are based on central evaluation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks","id":"OG000","title":"Regorafenib (Stivarga, BAY73-4506)"},{"description":"Participants received matching Placebo tablets per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set with response participants","reportingStatus":"POSTED","timeFrame":"From randomization of the first subject until date of database cutoff (26 Jan 2012); study duration approximately 1 year","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Days"}